Scientists have identified a crucial molecular switch that decides whether pancreatic cancer cells resist chemotherapy or respond to it. The key player, a gene called GATA6, keeps tumours in a more structured and treatable form—but it gets shut down by an overactive KRAS-driven pathway. When researchers blocked that pathway, GATA6 levels rebounded and cancer cells became more sensitive to chemo. The discovery could help turn some of the toughest pancreatic tumours into ones doctors can better control.
View the full article